Edition:
United Kingdom

Boston Scientific Corp (BSX.N)

BSX.N on New York Stock Exchange

36.11USD
3:18pm GMT
Change (% chg)

$-1.10 (-2.96%)
Prev Close
$37.21
Open
$37.15
Day's High
$37.15
Day's Low
$35.85
Volume
287,751
Avg. Vol
1,597,872
52-wk High
$39.43
52-wk Low
$24.54

Latest Key Developments (Source: Significant Developments)

Boston Scientific Receives U.S. FDA Approval For The Eluvia Drug-Eluting Vascular Stent System
Monday, 24 Sep 2018 

Sept 24 (Reuters) - Boston Scientific Corp ::BOSTON SCIENTIFIC RECEIVES U.S. FDA APPROVAL FOR THE ELUVIA DRUG-ELUTING VASCULAR STENT SYSTEM.  Full Article

Boston Scientific Announces Agreement To Acquire Augmenix, Inc.
Thursday, 6 Sep 2018 

Sept 6 (Reuters) - Boston Scientific Corp ::BOSTON SCIENTIFIC ANNOUNCES AGREEMENT TO ACQUIRE AUGMENIX, INC..BOSTON SCIENTIFIC ANNOUNCES AGREEMENT TO ACQUIRE AUGMENIX, INC..BOSTON SCIENTIFIC CORP - TRANSACTION CONSISTS OF AN UPFRONT CASH PAYMENT OF $500 MILLION, AND UP TO $100 MILLION FOR REACHING SALES-BASED MILESTONES..BOSTON SCIENTIFIC CORP - DEAL IS EXPECTED TO BE IMMATERIAL TO ADJUSTED EARNINGS PER SHARE IN 2018 AND 2019.BOSTON SCIENTIFIC CORP - TRANSACTION IS EXPECTED TO BE ACCRETIVE TO ADJUSTED EARNINGS PER SHARE IN 2020 AND INCREASINGLY ACCRETIVE THEREAFTER.BOSTON SCIENTIFIC CORP - ON A GAAP BASIS, TRANSACTION IS EXPECTED TO BE LESS ACCRETIVE, OR MORE DILUTIVE.  Full Article

Boston Scientific Corp Says Entered Into A $1 Bln Credit Agreement
Tuesday, 21 Aug 2018 

Aug 21 (Reuters) - Boston Scientific Corp ::BOSTON SCIENTIFIC CORP - ON AUGUST 20, ENTERED INTO A $1.000 BILLION CREDIT AGREEMENT - SEC FILING.BOSTON SCIENTIFIC CORP - 2018 CREDIT AGREEMENT PROVIDES FOR A $1 BILLION 364 DAY TERM LOAN, MATURING ON AUGUST 19, 2019.BOSTON SCIENTIFIC-MAY INCREASE 2018 TERM LOAN COMMITMENT/GIVE NEW TERM LOAN FACILITY UNDER THE AGREEMENT IN AMOUNT NOT TO EXCEED $500 MILLION ON PRIOR NOTICE.  Full Article

Jana Partners LLC Dissolves Sole Share Stake In Dropbox, Takes In Wells Fargo And Cuts in Teva
Tuesday, 14 Aug 2018 

Aug 14 (Reuters) - Jana Partners LLC::JANA PARTNERS LLC DISSOLVES SOLE SHARE STAKE IN DROPBOX INC - SEC FILING.JANA PARTNERS LLC TAKES SOLE SHARE STAKE OF 1.1 MILLION SHARES IN WELLS FARGO & CO.JANA PARTNERS LLC CUTS SOLE SHARE STAKE IN BOSTON SCIENTIFIC CORP BY 33.6 PERCENT TO 3.1 MILLION SHARES.JANA PARTNERS LLC CUTS SOLE SHARE STAKE IN TIFFANY & CO BY 50.5 PERCENT TO 1.8 MILLION SHARES.JANA PARTNERS LLC CUTS SOLE SHARE STAKE IN TEVA PHARMACEUTICAL INDUSTRIES LTD BY 15.5 PERCENT TO 2.9 MILLION SPONSORED ADRS.JANA PARTNERS LLC - CHANGE IN HOLDINGS ARE AS OF JUNE 30, 2018 AND COMPARED WITH THE PREVIOUS QUARTER ENDED AS OF MARCH 31, 2018.  Full Article

Boston Scientific Announces Agreement To Buy VENITI
Wednesday, 8 Aug 2018 

Aug 8 (Reuters) - Boston Scientific Corp ::BOSTON SCIENTIFIC ANNOUNCES AGREEMENT TO ACQUIRE VENITI, INC..BOSTON SCIENTIFIC CORP - TRANSACTION PRICE FOR REMAINING STAKE CONSISTS OF $108 MILLION UP-FRONT CASH.BOSTON SCIENTIFIC CORP - ACQUISITION OF VENITI IS EXPECTED TO BE IMMATERIAL TO BOSTON SCIENTIFIC ADJUSTED EARNINGS PER SHARE (EPS) IN 2018 AND 2019.BOSTON SCIENTIFIC - DEAL PRICE FOR REMAINING STAKE ALSO CONSISTS OF UP TO $52 MILLION IN PAYMENTS CONTINGENT UPON U.S. FDA APPROVAL OF VICI STENT SYSTEM.BOSTON SCIENTIFIC CORP - ON A GAAP BASIS FOR 2019 AND SUBSEQUENT YEARS, TRANSACTION IS EXPECTED TO BE LESS ACCRETIVE, OR MORE DILUTIVE AS CASE MAY BE.BOSTON SCIENTIFIC - DEAL TO BE IMMATERIAL TO BOSTON SCIENTIFIC ADJUSTED EARNINGS PER SHARE (EPS) IN 2018 AND 2019, AND ACCRETIVE THEREAFTER.BOSTON SCIENTIFIC CORP - FOR 2018 ON A GAAP BASIS, TRANSACTION IS EXPECTED TO BE ACCRETIVE DUE TO A ONE-TIME GAIN ON PRIOR INVESTMENT.  Full Article

Boston Scientific Agrees To Buy Claret Medical For $220 Mln In Up-Front Cash
Friday, 20 Jul 2018 

July 20 (Reuters) - Boston Scientific Corp ::BOSTON SCIENTIFIC ANNOUNCES AGREEMENT TO ACQUIRE CLARET MEDICAL, INC..BOSTON SCIENTIFIC CORP - TRANSACTION PRICE CONSISTS OF $220 MILLION IN UP-FRONT CASH.BOSTON SCIENTIFIC CORP - DEAL IS EXPECTED TO BE IMMATERIAL TO ADJUSTED EARNINGS PER SHARE IN 2018.BOSTON SCIENTIFIC CORP - TRANSACTION PRICE ALSO CONSISTS OF A POTENTIAL REIMBURSEMENT-BASED MILESTONE PAYMENT OF UP TO $50 MILLION.BOSTON SCIENTIFIC CORP - ON GAAP BASIS, TRANSACTION IS EXPECTED TO BE LESS ACCRETIVE, OR MORE DILUTIVE AS CASE MAY BE.BOSTON SCIENTIFIC - DEAL IS EXPECTED TO BE ACCRETIVE IN 2019 & INCREASINGLY ACCRETIVE THEREAFTER.  Full Article

Boston Scientific To Acquire Cryterion Medical
Thursday, 5 Jul 2018 

July 5 (Reuters) - Boston Scientific Corp ::BOSTON SCIENTIFIC TO ACQUIRE CRYTERION MEDICAL, INC..BOSTON SCIENTIFIC CORP - EXPECTS TRANSACTION TO BE IMMATERIAL ON AN ADJUSTED EARNINGS PER SHARE BASIS THROUGH 2020, AND ACCRETIVE THEREAFTER.BOSTON SCIENTIFIC CORP - FOR 2018 ON A GAAP BASIS, DEAL IS EXPECTED TO BE ACCRETIVE DUE TO A ONE-TIME GAIN ON PRIOR INVESTMENT.BOSTON SCIENTIFIC - TRANSACTION PRICE FOR ABOUT 65 PERCENT REMAINING STAKE OF CRYTERION NOT ALREADY OWNED BY CO CONSISTS OF $202 MILLION IN UP-FRONT CASH.BOSTON SCIENTIFIC CORP - ON GAAP BASIS FOR 2019 AND SUBSEQUENT YEARS, DEAL EXPECTED TO BE LESS ACCRETIVE OR MORE DILUTIVE AS CASE MAY BE.  Full Article

Jana Partners LLC Takes Sole Share Stake In Allergan, Boston Scientific
Tuesday, 15 May 2018 

May 15 (Reuters) - Jana Partners LLC ::JANA PARTNERS LLC TAKES SOLE SHARE STAKE IN ALLERGAN PLC OF 12,000 SHARES - SEC FILING.JANA PARTNERS LLC TAKES SOLE SHARE STAKE IN AGILENT TECHNOLOGIES INC OF 1.0 MILLION SHARES.JANA PARTNERS LLC TAKES SOLE SHARE STAKE IN ANTHEM INC OF 610,593 SHARES.JANA PARTNERS LLC DISSOLVES SOLE SHARE STAKE IN W W GRAINGER INC.JANA PARTNERS LLC TAKES SOLE SHARE STAKE IN BOSTON SCIENTIFIC CORP OF 4.7 MILLION SHARES.JANA PARTNERS LLC - CHANGE IN HOLDINGS ARE AS OF MARCH 31, 2018 AND COMPARED WITH THE PREVIOUS QUARTER ENDED AS OF DEC 31, 2017.  Full Article

Boston Scientific Closes NxThera Acquisition
Monday, 30 Apr 2018 

April 30 (Reuters) - Boston Scientific Corp ::BOSTON SCIENTIFIC CLOSES NXTHERA ACQUISITION.  Full Article

Boston Scientific Prevails In European Patent Dispute With Edwards Lifesciences
Monday, 16 Apr 2018 

April 16 (Reuters) - Boston Scientific Corp ::BOSTON SCIENTIFIC PREVAILS IN EUROPEAN PATENT DISPUTE WITH EDWARDS LIFESCIENCES.BOSTON SCIENTIFIC CORP - SUCCESSFULLY OPPOSED EDWARDS LIFESCIENCES' EUROPEAN PATENT EP 2,399,550, RESULTING IN REVOCATION OF PATENT.BOSTON SCIENTIFIC - GERMAN COURT OF APPEAL TO HAVE HEARING IN MAY, JUNE THIS YEAR ABOUT CO'S PATENTS '254, '766 THAT EDWARDS WAS FOUND TO INFRINGE.  Full Article

CORRECTED-FOCUS-U.S. regulators snip red tape for medical devices to curb opioid crisis

Nov 9 Laura Perryman expected her medical company, Stimwave Technologies Inc, would have to wait several years for its painkilling device to win U.S. approval as a treatment for chronic migraines.